Literature DB >> 31262591

Major Advancements in Slowing Diabetic Kidney Disease Progression: Focus on SGLT2 Inhibitors.

George L Bakris1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31262591     DOI： 10.1053/j.ajkd.2019.05.009

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  3 in total

Review 1.  Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale.

Authors:  Michele Provenzano; Giuseppe Coppolino; Luca De Nicola; Raffaele Serra; Carlo Garofalo; Michele Andreucci; Davide Bolignano
Journal:  Front Cell Dev Biol       Date:  2019-12-03

2.  SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection.

Authors:  Lakshini Y Herat; Aaron L Magno; Caroline Rudnicka; Jana Hricova; Revathy Carnagarin; Natalie C Ward; Angelique Arcambal; Marcio G Kiuchi; Geoff A Head; Markus P Schlaich; Vance B Matthews
Journal:  JACC Basic Transl Sci       Date:  2020-01-29

Review 3.  Potential Safety Issues with Use of Sodium-Glucose Cotransporter 2 Inhibitors, Particularly in People with Type 2 Diabetes and Chronic Kidney Disease.

Authors:  Tamara Y Milder; Sophie L Stocker; Richard O Day; Jerry R Greenfield
Journal:  Drug Saf       Date:  2020-10-23       Impact factor: 5.606
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.